Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials

被引:28
作者
Budach, Wilfried [1 ]
Bolke, Edwin [1 ]
Matuschek, Christiane [1 ]
机构
[1] Univ Dusseldorf, Dept Radiat Oncol, D-40225 Dusseldorf, Germany
关键词
Breast cancer; Radiotherapy; Hypofractionation; Hypofractionated; Adjuvant; Meta-analysis; CONSERVING THERAPY; FOLLOW-UP; FRACTIONATION SCHEDULE; DOSE-RESPONSE; STAGE-I; IRRADIATION; TRASTUZUMAB; MASTECTOMY; LUMPECTOMY; WOMEN;
D O I
10.1159/000439007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Adjuvant radiotherapy after breast-conserving surgery is indicated in the vast majority of breast cancer patients. Conventionally fractionated radiotherapy with 50 Gy in 25 fractions was considered standard of care for several decades. The recently publishes long-term results of randomized trials that have tested different moderately hypofractionated radiotherapy schedules that may change clinical practice. Patients and Methods: A Pubmed search was carried out to identify the relevant publications on hypofractionated radiotherapy in breast cancer. In total, 4 randomized controlled trials representing the results of 7,095 patients with 10 years of follow-up were identified. A meta-analysis on the primary end point ipsilateral breast cancer recurrence and a review of the toxicity data were performed. Results: Moderately hypofractionated radiotherapy using schedules such as 40 Gy in 15 fractions administered within 3 weeks are as efficient and safe as conventionally fractionated radiotherapy for most breast cancer patients who need adjuvant radiotherapy after breast-conserving surgery. In patients aged < 40 years, after neoadjuvant chemotherapy, and if regional lymph node radiotherapy is indicated, further data are needed. Conclusion: Moderately hypofractionated radiotherapy can be recommended as standard treatment after breast-conserving surgery in the majority of breast cancer patients. (C) 2015 S. Karger GmbH, Freiburg
引用
收藏
页码:240 / 245
页数:6
相关论文
共 38 条
[1]  
Ash D V, 1995, Clin Oncol (R Coll Radiol), V7, P93, DOI 10.1016/S0936-6555(05)80808-8
[2]   Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy [J].
Bane, A. L. ;
Whelan, T. J. ;
Pond, G. R. ;
Parpia, S. ;
Gohla, G. ;
Fyles, A. W. ;
Pignol, J. -P. ;
Pritchard, K. I. ;
Chambers, S. ;
Levine, M. N. .
ANNALS OF ONCOLOGY, 2014, 25 (05) :992-998
[3]  
Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7
[4]  
Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]
[5]   Radiotherapy of invasive breast cancer: French national guidelines [J].
Besnard, S. ;
Cutuli, B. ;
Fourquet, A. ;
Giard, S. ;
Hennequin, C. ;
Leblanc-Onfroy, M. ;
Mazeau-Woynar, V. ;
Verdoni, L. .
CANCER RADIOTHERAPIE, 2012, 16 (5-6) :503-513
[6]   Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update [J].
Clark, RM ;
Whelan, T ;
Levine, M ;
Roberts, R ;
Willan, A ;
McCulloch, P ;
Lipa, M ;
Wilkinson, RH ;
Mahoney, LJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22) :1659-1664
[7]   Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer - A study based on the EORTC trial 22881-10882 'boost versus no boost' [J].
Collette, Sandra ;
Collette, Laurence ;
Budiharto, Tom ;
Horiot, Jean-Claude ;
Poortmans, Philip M. ;
Struikmans, Henk ;
Van den Bogaer, Walter ;
Fourquet, Alain ;
Jagerg, Jos J. ;
Hoogenraad, Willem ;
Mueller, Rolf-Peter ;
Kurtz, John ;
Morgan, David A. L. ;
Dubois, Jean-Bernard ;
Salamon, Emile ;
Mirimanoff, Rene ;
Bolla, Michel ;
Van der Hulst, Marleen ;
Warlam-Rodenhuis, Carla C. ;
Bartelink, Harry .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (17) :2587-2599
[8]  
Dellas K, 2014, STRAHLENTHER ONKOL, V190, P646, DOI 10.1007/s00066-014-0658-5
[9]   Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials [J].
Darby S. ;
McGale P. ;
Correa C. ;
Taylor C. ;
Arriagada R. ;
Clarke M. ;
Cutter D. ;
Davies C. ;
Ewertz M. ;
Godwin J. ;
Gray R. ;
Pierce L. ;
Whelan T. ;
Wang Y. ;
Peto R. ;
Albain K. ;
Anderson S. ;
Barlow W. ;
Bergh J. ;
Bliss J. ;
Buyse M. ;
Cameron D. ;
Carrasco E. ;
Coates A. ;
Collins R. ;
Costantino J. ;
Cuzick J. ;
Davidson N. ;
Davies K. ;
Delmestri A. ;
Di Leo A. ;
Dowsett M. ;
Elphinstone P. ;
Evans V. ;
Gelber R. ;
Gettins L. ;
Geyer C. ;
Goldhirsch A. ;
Gregory C. ;
Hayes D. ;
Hill C. ;
Ingle J. ;
Jakesz R. ;
James S. ;
Kaufmann M. ;
Kerr A. ;
MacKinnon E. ;
McHugh T. ;
Norton L. ;
Ohashi Y. .
LANCET, 2011, 378 (9804) :1707-1716
[10]   The impact of radiotherapy, trastuzumab and hormonal therapy on cardiac fibrosis. More is worse? [J].
Farolfi, Alberto .
ANATOLIAN JOURNAL OF CARDIOLOGY, 2014, 14 (04) :334-335